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Abstract
Background Non-adherence to antipsychotic therapy
among patients with schizophrenia is a key driver of
relapse, which can lead to costly inpatient stays. Long-
acting injectables (LAIs) may improve adherence, thus
reducing hospitalizations, but inpatient cost reductions
need to be balanced against higher drug acquisition costs of
LAIs. Real-world evidence is needed to help quantify the
economic value of oral atypical antipsychotics compared
with LAIs.
Objective The objective of this study was to compare
healthcare costs and resource utilization between once-
monthly paliperidone palmitate (PP) and oral antipsychotic
therapy (OAT) in a population of Medicaid beneficiaries
with schizophrenia.
Methods A retrospective, observational study was per-
formed using Truven Health MarketScan Medicaid claims
data from 2009 to 2012. Marginal structural modeling, a
form of weighted repeated measures analysis to control for
differences between cohorts and time-varying confound-
ing, was used to estimate monthly costs of care in 2012 US
dollars and resource utilization over a 12-month period for
patients in each cohort.
Results While per-month mental-health prescription costs
were US$1019 higher in the PP cohort, approximately
55 % of this premium was offset by lower inpatient and
outpatient care costs, producing a mean monthly total cost
differential of US$434 (95 % CI 298–569, p\ 0.0001) for
all-cause costs and US$463 (95 % CI 374–552,
p\ 0.0001) for mental-health-related costs. Use of PP also
resulted in a 0.44 and 0.47 reduction in the odds of all-
cause and mental-health-related hospitalizations and a 0.09
reduction in the odds of all-cause emergency department
visits (p\ 0.0001, p\ 0.0001, and p = 0.0134, respec-
tively) over the 12-month follow-up period.
Conclusions Treatment with long-acting injectable an-
tipsychotics, such as PP, may reduce inpatient and outpa-
tient healthcare services utilization and associated costs.
These findings also suggest that patients with schizophrenia
taking once-monthly PP may stand a lower risk of hospi-
talization than patients on OAT.
Key Points
While the paliperidone palmitate (PP) cohort had
higher mental-health prescription costs compared
with the oral antipsychotic therapy (OAT) cohort,
over half of the acquisition costs were offset by
lower inpatient and outpatient care costs.
PP use showed reductions in the odds of inpatient
and outpatient healthcare utilization and associated
costs over the 12-month follow-up period.
The study suggests that patients with schizophrenia
taking once-monthly PP may experience less
inpatient and outpatient healthcare services
utilization and associated costs than patients taking
OAT.
& Jacqueline A. Pesa
jpesa@its.jnj.com
1 Janssen Scientific Affairs, LLC, 3133 Castle Peak Ave.
Superior, Louisville, CO 80027, USA
2 Truven Health Analytics, Cambridge, USA
Drugs - Real World Outcomes (2015) 2:377–385
DOI 10.1007/s40801-015-0043-4
1 Introduction
Schizophrenia is a chronic, complex, and devastating
mental illness, long recognized as costly and challenging to
treat [1–3]. The economic impact of schizophrenia attrib-
uted to direct healthcare costs alone was estimated at
US$22.7 billion in the United States (2002 US dollars) [3].
Estimates of mean annual direct medical costs among
community-dwelling patients with schizophrenia range
from US$3700 to US$27,900 per patient; inpatient costs
comprise 10–30 % of these costs [4]. In a recent study of
schizophrenia patients with Medicaid coverage, annual
mental-health-related medical costs for patients prescribed
atypical antipsychotics were US$11,700 per patient [5].
Relapse associated with schizophrenia is a key driver of
costs [6], principally due to the need for inpatient care.
Moreover, as the number of patient relapses increases,
inpatient costs disproportionally accelerate [7]; thus,
relapse prevention is a key goal in effectively managing
schizophrenic patient populations [8]. A significant driver
of relapse and subsequent hospitalization or acute care is
the frequent non-adherence to antipsychotic therapy among
patients with schizophrenia [9]. In fact, a recent estimate
provided by the US Department of Health and Human
Services revealed that just 61 % of Medicaid patients with
schizophrenia continuously refilled their antipsychotic
prescriptions [10]. This underscores the need for therapies
that may improve adherence, such as long-acting
injectable (LAI) antipsychotics, which have demonstrated
enhanced adherence [11], thus potentially reducing rates of
relapse and hospitalization among patients with
schizophrenia [12]. This, however, needs to be balanced
against higher drug acquisition costs as well as the cost of
administration often associated with LAIs [13].
Paliperidone palmitate long-acting injection (PP) is
indicated for the treatment of schizophrenia in adults and
has been available in the US since 2009. PP is an
injectable antipsychotic medication administered monthly
by a healthcare professional, which differs from oral
antipsychotic therapy (OAT) that requires patients to take
medication daily. There is a body of literature to date
demonstrating improved economic outcomes for patients
treated with PP; however, most of these studies are either
from clinical trials [14] or economic models [15–17]. A
recent study of Veterans Affairs patients with schizophre-
nia treated with PP compared with those treated with OAT
showed lower inpatient admission rates and costs for the
PP-treated group over the observed 1-year follow-up period
[18]. A study in a Medicaid sample recently demonstrated
a lower likelihood of emergency department visits among
patients treated with PP [11]. A meta-analysis study also
suggested that LAIs are associated with greater reductions
in hospitalization rates compared with OATs [19]. There is
a need for additional real-world evidence accumulated
through comparative outcomes studies, to help inform
formulary and policy decision makers about the value of
LAIs compared with oral atypical antipsychotics for the
treatment of schizophrenia. The present study was designed
to build upon previous research, especially by expanding
the size of the data set and increasing the geographic dis-
persion of the sample in the US. The primary objective of
the study was to compare costs and resource utilization
among Medicaid patients diagnosed with schizophrenia
who were treated with either PP or OAT in a real-world
setting.
2 Methods
This study retrospectively compared costs and resource
utilization among Medicaid patients diagnosed with
schizophrenia who were treated with PP versus OAT.
Specifically, PP and OAT patients were compared with
respect to demographic and clinical characteristics in the
6 months prior to initiation (baseline or run-in period) of
PP or OAT and the healthcare utilization and costs in the
baseline period and 12-month post-initiation period (fol-
low-up). Healthcare utilization and direct healthcare costs
were analyzed with inverse probability of treatment
weights (IPTW) and marginal structural modeling (MSM)
to estimate these outcomes while controlling for imbal-
ances in covariates between the PP and the OAT cohorts,
including demographic and clinical characteristics and
events, such as treatment decisions, that occur not only at
index but over time.
2.1 Study Sample
Patients in this study were identified from the MarketScan
Medicaid Multi-State Database (Truven Health Analytics,
Ann Arbor, MI, USA). This database contains the de-
identified healthcare claims of Medicaid enrollees from
twelve geographically diverse states. Patients who met the
inclusion and exclusion criteria for either the PP or OAT
cohort, detailed below, were included in the study and
followed over 12 months.
The PP cohort included patients with two or more pre-
scription drug or medical claims for PP, no more than
90 days apart, during the cohort selection period of July
2009 through December 2011. The earliest such claim was
set as the index date (day 1). Because of the US launch date
for PP (August 2009), all patients were newly started on PP
as of the index date. Patients were required to have con-
tinuous enrollment 6 months before and 12 months after
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the index date (the ‘study period’), be at least 18 years old
at index, and have evidence of schizophrenia during the
study period, defined as two or more claims with ICD-9
295.1x, 295.2x, 295.3x, 295.6x, 295.8x, or 295.9x, or one
or more claim with ICD-9 295.7x plus one or more claim
with ICD-9 295.1x, 295.2x, 295.3x, 295.6x, 295.8x, or
295.9x. In order to ensure that medication claims histories
were as complete as possible, patients with Medicare dual
eligibility and/or a mental health carve-out plan were
excluded. Other therapies were not precluded during the
study period so PP cohort patients could have had claims
for OAT or a LAI antipsychotic other than PP at any point
before or after index.
The OAT cohort was identified from among patients
with no claims for PP between 2009 and 2012, in order to
create mutually exclusive cohorts at index. Patients with
two or more prescription claims for the same oral atypical
antipsychotic (aripiprazole, asenapine, iloperidone, lurasi-
done, olanzapine [including combination olanzapine/flu-
oxetine], paliperidone, quetiapine, risperidone, or
ziprasidone) on different dates, no more than 90 days apart,
during the cohort selection period of July 2009 through
December 2011 were identified. The earliest such claim
was set as the index date (day 1). Patients with claims for
the index antipsychotic in the 6 months pre-index were
excluded so that all patients would be newly starting
treatment with the index OAT on the index date. The
continuous enrollment, age, diagnostic criteria, Medicare
dual eligibility and carve-out criteria for the OAT cohort
were the same as described above for the PP cohort. Use of
PP by patients in the OAT cohort was precluded as a
function of sample selection, but patients in the OAT
cohort could have used non-index OATs or LAI antipsy-
chotics other than PP at any point before or after index.
2.2 Study Variables
The primary outcomes for this study were differences in
healthcare costs and healthcare utilization when OAT and
PP cohorts were compared. Healthcare costs were identi-
fied by type of service and were calculated in two ways:
all-cause and mental-health related. Mental-health-related
costs were identified based on the primary/first diagnosis
coded (ICD-9-CM 290.xx–319.xx) on each claim for out-
patient and inpatient services and by pharmacy claims for
all classes of psychiatric medications. Monthly costs in
each of the two categories were calculated in 30-day
increments, starting from the index date (day 1), such that
month 1 costs were those incurred from days 1 through day
30, month 2 costs were those incurred from day 31 through
day 60, etcetera. All costs were inflation adjusted to 2012
US dollars using the Medical Care Component of the
Consumer Price Index.
Healthcare utilization was similarly defined in two
ways: all-cause and mental-health related. Binary measures
of any utilization, as well as a count of the number of
services incurred, were computed for inpatient admissions,
emergency department visits, outpatient office visits, and
other outpatient services. Monthly utilization rates were
calculated in 30-day increments, starting from the index
date, as described above for costs.
2.3 Study Analyses
In order to account for potential time-varying confounding
that may occur across cohorts, multivariate analyses using
MSM were conducted. MSM is a weighted repeated mea-
sures analysis with treatment as a time-varying covariate. It
differs from the typical intent-to-treat modeling approach
in that the MSM accounts for the fact that treatment
decisions occur not only prior to index but over time. It
also helps control for events that occur during the study
period that may impact both post-index treatment decisions
and outcomes of interest (e.g., hospitalization) that may be
evident in claims data and can influence both subsequent
treatment and outcomes.
MSM based on the Faries et al. methodology [20] were
conducted to assess cost and utilization outcomes, while
controlling for differences between cohorts and over time.
Weights based on IPTW were calculated in a multi-step
process. First, two weights were calculated for each patient
using logistic regression. The clinical characteristics in
Table 1, measured monthly over the study period, were
time-varying covariates in the regressions and the demo-
graphics characteristics in Table 1, measured at index,
were non time-varying covariates. The first weight adjusted
for treatment with PP (no or yes), and the second weight,
relevant only for the PP cohort, adjusted for whether
treatment with PP discontinued (no or yes). These two
weights were then merged to form a stabilized weight as
recommended in Herna´n et al. [21]. Very large stabilized
weights can be problematic in the analysis because these
outliers represent almost certain assignment to a particular
group, hence patients with large weights ([30) were
excluded from the MSM analysis. The value of 30 was
thought to represent a reasonable compromise and was in
line with the value used in other similar research. Next, a
weighted repeated measures analysis of outcomes was
performed, using a generalized estimating equation (GEE)
approach. The GEE analysis used link functions and error
distributions appropriate for the type of outcome; for
example, log link and gamma error distribution for costs. In
this fashion, per-patient, per-month costs could be ana-
lyzed. The same set of covariates as the second logistic
regression together with the two variates treatment with PP
and discontinuation of PP were covariates in the GEE
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Table 1 Baseline demographic and clinical characteristics of the study sample





N/mean %/SD N/mean %/SD
Demographics
Age (mean, SD) Index date 38.8 12.3 41.6 12.9 \0.001
Male (n, %) Index date 573 58.2 % 2049 48.8 % \0.001
Race/ethnicity (n, %) Index date
White 377 38.3 % 1789 42.6 % 0.014
Black 511 51.9 % 1987 47.3 % 0.009
Other 96 9.8 % 423 10.1 % 0.765
Residence in MSAa (n, %) Index date 734 74.6 % 3033 72.2 % 0.135
Capitated health plan (n, %) Index date 366 37.2 % 2224 53.0 % \0.001
Clinical characteristics
Type of schizophreniab (n, %) Most recent
All except schizoaffective 738 75.0 % 3236 77.1 % 0.168
Schizoaffective disorder 246 25.0 % 963 22.9 % 0.168
Charlson Comorbidity Indexb (mean, SD) Prior 6 months 0.5 1.0 0.8 1.4 \0.001
Mental health diagnosesb (mean, SD) Prior 6 months 3.2 2.3 3.4 2.3 0.014
Comorbiditiesb (n, %) Prior 6 months
Depression 270 27.4 % 1572 37.4 % \0.001
Bipolar disorder 279 28.4 % 1436 34.2 % 0.001
Anxiety 57 5.8 % 222 5.3 % 0.527
Alcohol or substance abuse 122 12.4 % 539 12.8 % 0.711
Unique antipsychotic agentsc (n, %) Prior 3 months
\2 unique agents 531 54.0 % 1197 28.5 % \0.001
C2 unique agents 453 46.0 % 3002 71.5 % \0.001
Antipsychotic PDCc,d (mean, SD) Prior 3 months 0.7 0.3 0.7 0.4 [0.999
Other medication utilizationd (n, %) Prior 6 months
Long-acting injectable antipsychoticse 269 27.3 % 860 20.5 % \0.001
Antidepressants 518 52.6 % 2564 61.1 % \0.001
Mood stabilizers 417 42.4 % 1830 43.6 % 0.493
Anxiolytics 306 31.1 % 1622 38.6 % \0.001
Emergency department visit (n, %) Prior 1 months 438 44.5 % 2147 51.1 % \0.001
Inpatient admission (n, %) Prior 3 months 363 36.9 % 1796 42.8 % 0.001
Healthcare expenditures (mean, SD) Prior 6 months
Totalf $19,431 $21,816 $22,070 $37,441 0.004
Mental-health relatedf $15,891 $19,773 $13,526 $17,946 0.001
Table presents metrics for Month 1 which started on the Index Date (day 1) and continued to day 30. Variables measured in the prior 1–6 months
were compiled from claims prior to, but not including, the Index Date. The modeling employed the same variables measured for each of the
12 months of the study period (e.g., days 1–30, days 31–60, days 61–90, etc.)
MSAs Metropolitan statistical areas, OAT oral antipsychotic therapy, PDC proportion of days covered, PP paliperidone palmitate
a MSAs include cities with population[50,000 and urban areas with population[100,000. Non-MSAs are generally rural communities
b Unique diagnoses codes measured from relevant ICD-9 codes listed on inpatient and outpatient services claims
c PDC = days in past 90 days with any antipsychotic on hand (determined from medication claims), divided by 90
d Measured from outpatient pharmacy claims and, for injectables, also from outpatient services claims
e Includes agents other than PP
f Values are in 2012 US dollars
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analysis. The justification for this type of approach is that
the ability to control for time-varying confounding
accounted for the inter-cohort imbalances in covariates,
which were observed across the 12-month study period.
In this study, every patient had a full 12 months of
continuous enrollment so no patients discontinued from the
study. However, patients could be non-adherent, discon-
tinue or switch treatments, or discontinue treatment
entirely. Because of the way the patients were selected,
OAT patients could not switch to PP, which means that
patients initially assigned PP could have discontinued it,
switched to OAT, switched to an injectable other than PP,
or stopped treatment altogether; and that patients initially
assigned OAT could have discontinued their index OAT,
switched to another OAT, switched to an injectable other
than PP, or stopped treatment altogether. It was felt that
this is too many alternatives to be practical to include in
what is already a complex analysis. Restricting comparison
to a two-group one (i.e., PP vs OAT) and with the way the
coding was done (in particular that for discontinuation of
PP), it is assumed for the analysis that there is no discon-
tinuation of OAT for those patients initially assigned to the
OAT group, and that those patients in the PP group who
discontinue with PP switch to OAT. In addition, there is a
resemblance to an intent-to-treat approach in that any
treatment other than PP or OAT is implicitly assumed to be
OAT.
3 Results
The MarketScan Medicaid Multi-State Database contained
4778 patients initiating PP and 241,557 non-PP patients
initiating OAT between the years 2009–2011. A higher
percentage of patients in the PP cohort compared with the
OAT cohort (66 vs 12 %) remained after applying the
schizophrenia diagnosis criterion. After applying all
inclusion and exclusion criteria, the final study sample
contained 984 patients in the PP cohort and 4199 patients
in the OAT cohort.
The baseline characteristics of the study sample are
detailed in Table 1. Patients in the PP cohort were slightly
younger than the OAT patients (38.8 vs 41.6 years,
p\ 0.001). There was a slightly higher percentage of males
in the PP cohort (58.2 vs 48.8 %, p\ 0.001). A lower
percentage of patients in the PP cohort than the OAT cohort
identified as White (38.3 vs 42.6 %, p = 0.014), and a
higher percentage identified as Black (51.9 vs 47.3 %,
p = 0.009). Finally, a greater percentage of patients in the
OAT cohort were members of a capitated health plan than
patients in the PP cohort (53.0 vs 37.2 %, p\ 0.001).
Clinically, the cohorts were similar with respect to the
composition of patients with a primary schizophrenia
subtype versus schizoaffective disorder (75.0 vs 77.1 %,
p = 0.168). The mean prior 6-month Charlson Comor-
bidity Index score was statistically significantly higher in
the OAT cohort (0.8 vs 0.5, p\ 0.001). Patients in the
OAT cohort also tended to have more unique mental health
diagnoses (3.4 vs 3.2, p = 0.014) and there was a higher
frequency in this cohort of comorbidity with depression
(37.4 vs 27.4 %, p\ 0.001) and bipolar disorder (34.2 vs
28.4 %, p = 0.001).
In terms of recent treatment, patients in the OAT cohort
were more frequently exposed to two or more unique
antipsychotic agents in the previous 90 days (71.5 vs
46.0 %, p\ 0.001), and the mix of classes of psychotropic
drugs differed between the two cohorts in the preceding
6 months. With respect to general medical care, there were
a greater percentage of patients with an emergency
department (ED) visit (51.1 vs 44.5 %, p\ 0.001) and/or
inpatient admission in the OAT cohort (42.8 vs 36.9 %,
p = 0.001), and their total healthcare expenditures tended
to be higher (US$22,070 vs US$19,431, p = 0.004). At
baseline, expenditures for mental-health-related care were
higher in the PP cohort (US$15,891 vs US$13,526,
p = 0.001).
After creation of stabilized weights for the MSM
analysis and review of their distribution, it was determined
that weights with a value [30 were outliers, and that
observations with these weights should be excluded. A
total of 87 patients, 20 of whom were in the PP cohort,
had outlier stabilized weights and hence had observations
excluded from the MSM analysis of cost and utilization
outcomes.
After MSM adjustment to control for differences
between cohorts, the mean cost differential between
cohorts with respect to total and component costs (all-cause
and mental-health related) was estimated (Table 2).
Monthly prescription drug costs for patients in the PP
cohort were higher than costs for patients in the OAT
cohort, with respect to both all-cause pharmacy costs
(US$1004; 95 % confidence interval [CI] 986–1021,
p\ 0.0001) and mental-health-related costs (US$1019;
95 % CI 1005–1034, p\ 0.0001). On the other hand, costs
for other components of care, including inpatient and
outpatient medical treatment, were lower in the PP cohort
than the OAT cohort. Costs for inpatient services were
lower, both in terms of all-cause costs (-US$234; 95 % CI
-362 to -107, p = 0.0003) and costs specific to mental-
health-related care (-US$271; 95 % CI -355 to -186,
p\ 0.0001). Similarly, costs for outpatient services, driven
largely by costs other than office visits, were lower for the
patients in the PP cohort, when considering all-cause costs
(-US$336; 95 % CI -382 to -290, p\ 0.0001) and those
costs specific to mental-health care (-US$286; 95 % CI
-318 to -254, p\ 0.0001).
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Thus, approximately 55 % of the mental-health-related
prescription drug cost premium associated with PP was
offset by lower costs of mental-health-related inpatient and
outpatient care for these patients, producing a mean
monthly total cost differential of US$434 (95 % CI
298–569, p\ 0.0001) when accounting for all-cause costs
or US$463 (95 % CI 374–552, p\ 0.0001), accounting for
mental-health-related costs.
Across the follow-up period, the use of PP as compared
with OAT was associated with lower risk of healthcare
resource utilization, on a per-month, per-patient basis
(Table 3). For the PP cohort, the risk of an inpatient hos-
pital admission was statistically significantly lower for both
all-cause (by 36 %; 95 % CI 40–30, p\ 0.0001) and
mental-health-related utilization (by 38 %; 95 % CI 43–32,
p\ 0.0001). The risk of an ED visit for all causes was also
lower (by 18 %; 95 % CI 21–15, p = 0.0134).
4 Discussion
These results indicate that treatment with PP was associ-
ated with significantly lower inpatient admissions, lower
inpatient costs, and lower outpatient costs compared with
OAT treatment, which partially offset over half of the
incremental drug acquisition costs. This information should
prove valuable to healthcare decision makers and providers
when selecting an appropriate treatment for patients with
schizophrenia. The selection would be based on many
factors, including effectiveness and total cost of care,
which is comprised of drug acquisition cost and the cost of
outcomes (i.e., hospitalization due to relapse, ED visits),
both in terms of healthcare dollars and non-monetary costs
(i.e., disruption to patients and caregivers).
The methods employed to control for differences
between cohorts, both at index and over the follow-up
period of the analysis, included IPTW and MSM. Given
certain demographic, economic, and clinical differences
between the two cohorts at baseline, such as a signifi-
cantly higher incidence of mood disorder in the OAT
cohort and higher mental-health-related costs in the
6 months pre-index, it was important to use this type of
statistical methodology to answer the present research
questions. The changing nature of certain variables over
time may exert an influence on both treatment selection
and measured outcomes, justifying the need to control for
such time-dependent covariates with appropriate method-
ologies such as MSM. Studies that fail to account for the
effect of time-dependent covariates may present biased
results.
Table 2 Mean adjusted per-
month per-patient cost
differential associated with PP
utilization over 12 months post-
index
Cost parameter Estimate Wald 95 % confidence limits ProbChiSq
Lower Upper
All-cause costs
Inpatient costs -234.19 -361.70 -106.67 0.0003
Emergency department costs -5.14 -11.64 1.35 0.1208
Outpatient costs -335.89 -382.11 -289.67 \0.0001
Outpatient office visit costs -0.55 -2.13 1.02 0.4922
Other outpatient costs -330.19 -375.29 -285.09 \0.0001
Pharmacy costs 1003.65 986.21 1021.09 \0.0001
Total costsa 433.58 297.88 569.27 \0.0001
Mental-health-related costsb
Inpatient costs -270.56 -354.67 -186.45 \0.0001
Emergency department costs -0.22 -2.79 2.35 0.8658
Outpatient costs -285.94 -317.70 -254.17 \0.0001
Outpatient office visit costs 2.81 2.10 3.52 \0.0001
Other outpatient costs -288.52 -320.12 -256.93 \0.0001
Pharmacy costs 1019.30 1004.50 1034.10 \0.0001
Total costsa 462.80 373.95 551.65 \0.0001
Values are in 2012 US dollars
Reflects the mean monthly cost differential for patient months with PP compared to without PP, adjusted
for the covariates shown in Table 1
PP paliperidone palmitate
a Components do not sum to total costs because each cost parameter was modeled separately
b Includes claims with a primary diagnosis of ICD-9 290.xx–319.xx and pharmacy claims for all classes of
psychiatric medications
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Consistent with the findings of the current study, several
studies conducted in the US and various countries world-
wide have shown the incremental benefit of PP over OAT
and other LAIs. Kozma et al., for example, reported a
significant reduction in hospitalizations for patients with
schizophrenia treated with PP compared with placebo and
from prior to the trial to the end of the open-label phase of
a double-blind randomized controlled trial [14]. In Sweden,
a Markov model demonstrated the economic benefits of PP
compared with long-acting formulations of risperidone and
olanzapine [22]. Other studies have similarly demonstrated
the initial promise of PP, in terms of reduced rates of
relapse, medical costs, healthcare utilization, and quality-
adjusted life-years [13, 19, 23, 24].
The findings from previous real-world studies compar-
ing outcomes among Medicaid patients with schizophrenia
treated with PP and patients prescribed OAT are consistent
with the findings presented from this study [11, 25].
A Missouri Medicaid study, for example, reported a 37 %
reduction in the adjusted odds ratio for all-cause ED visits
(AOR: 0.63), and lower adjusted odds ratio for all-cause
and mental health-related hospitalizations in a propensity-
score matched cohort of patients administered PP and
patients prescribed OATs, with the ED difference at a
statistically significant level [11]. While the differences in
rate reductions between PP and OAT cohorts in our study
are more pronounced (particularly with respect to the
reduction of inpatient admissions) compared with the
Missouri Medicaid study, they are directionally similar and
provide further evidence of the benefit of PP in improving
healthcare resource utilization-related outcomes.
This study’s findings are also consistent with those from
a claims-based study of Veterans Heath Administration
patients with schizophrenia which revealed that patients
treated with PP had lower mean inpatient costs (US$18,560
vs US$31,505, p = 0.002), lower hospitalization rate (34
vs 53 %, p\ 0.001), and fewer average inpatient days
(13.24 vs 24.18, p = 0.002) when compared with matched
patients treated with OAT. While mean drug costs were
higher for PP patients (US$10,063 vs US$4167, p\ 0.001)
than OAT patients, mean total healthcare costs were sim-
ilar between the groups (US$45,529 vs US$52,569,
p = 0.128) [18].
Contrary to the findings of the current study, a meta-
analysis of randomized clinical trial results showed no
difference in the rate of relapse and hospitalization between
LAIs and OAT [26]. It could be that clinical trials, while
vital to understanding the efficacy of antipsychotic agents,
are not especially well suited to comparing LAIs and OATs
on outcomes that may be associated with medication
adherence because researcher monitoring throughout con-
trolled trials minimizes the possibility of treatment non-
adherence [27]. Thus, observational studies such as the
current study may be especially useful in understanding
how agents like PP may impact treatment outcomes in real-
world settings. Consistent with this study’s findings, a
meta-analysis of mirror-image studies [28] as well as a
meta-analysis of interventional and non-interventional
studies using meta-regressions [19] suggested a benefit of
LAI over OAT. This study adds to the existing body of
observational research on this topic by employing MSM
methodology that controls for time-dependent covariates to
minimize bias.
Results of this study should be interpreted in light of
certain limitations. Schizophrenia diagnoses were identi-
fied from healthcare claims coded for reimbursement rather
than diagnostic purposes, thus misclassification was pos-
sible. Cohort assignment at index was based on healthcare
claims that may be subject to measurement error. Similarly,
administration of PP and initiation of OAT on the date
listed on the claim was assumed, but could not be verified
from the data. In terms of the present database, inpatient
administration of PP could not be measured, thus some
patients who appeared to have discontinuous therapy may
have received injections while hospitalized. Additionally,
costs for outpatient acquisition and administration of PP
may have been included under pharmacy and/or outpatient
services, depending on the requirements of the various state
Table 3 Adjusted per-month
per-patient utilization risk ratios
associated with PP utilization
over 12 months post-index
Cost parameter Estimate Wald 95 % confidence limits ProbChiSq
Lower Upper
All-cause utilization
Any inpatient admission 0.6441 0.5954 0.6967 \0.0001
Any emergency department visit 0.8228 0.7892 0.8468 0.0134
Mental health-related utilizationa
Any inpatient admission 0.6235 0.5731 0.6779 \0.0001
Any emergency department visit 1.0539 0.9491 1.1587 0.1883
Calculated from odds ratios on a logit scale and adjusted for the covariates shown in Table 1
PP paliperidone palmitate
a Includes claims with a primary diagnosis of ICD-9 290.xx–319.xx
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Medicaid plans included in the database. Medication dos-
ing may have impacted costs and outcomes, but was not
measured for either cohort as part of this study. Study
results are reflective of a multi-state Medicaid population,
but may not be generalizeable to non-Medicaid patient
populations. Also, the assumptions about the data men-
tioned in the Methods section and those inherent to per-
forming a complex MSM analysis could be leading to some
biases in the results.
5 Conclusion
Due to the complexity of clinical management of
schizophrenia, the propensity for patients to relapse and
require re-hospitalization is high [3, 7]. The prevention of
relapse in schizophrenia remains a major public health
challenge and continuous long-term antipsychotic therapy
is considered essential to control symptoms and costly
hospitalizations [8]. This study demonstrates that treatment
with PP may address the propensity for relapse in this
patient population, thereby reducing the rate of utilization
of other healthcare services, while offsetting greater than
half of its acquisition costs.
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